Table 3.
Analysis of risk factors for the development of HCC based on the levels of serum tumor markers.
| Markers | HCC (n) | Non-HCC (n) | Cumulative incidence (CI) | Relative Risk (RR) | Attributable Risk (AR) | Attributable Risk Percent (ARP) | Chi-Square | p Value | |
|---|---|---|---|---|---|---|---|---|---|
| ALB (g/l) | Positive groups | 23 | 54 | 29.87% | 1.06 | 1.75% | 5.84% | 0.033 | 0.855 |
| Negative groups | 9 | 23 | 28.13% | ||||||
|
| |||||||||
| TBIL (μmol/L) | Positive groups | 21 | 44 | 32.31% | 1.09 | 2.76% | 8.55% | 0.093 | 0.760 |
| Negative groups | 13 | 31 | 29.55% | ||||||
|
| |||||||||
| ALT (U/L) | Positive groups | 24 | 30 | 44.44% | 2.72 | 28.08% | 63.18% | 10.178 | 0.001 |
| Negative groups | 9 | 46 | 16.36% | ||||||
|
| |||||||||
| PLT (109/L) | Positive groups | 27 | 59 | 31.40% | 1.20 | 5.31% | 16.91% | 0.242 | 0.623 |
| Negative groups | 6 | 17 | 26.09% | ||||||
|
| |||||||||
| PT(s) (s) | Positive groups | 20 | 49 | 28.99% | 0.97 | −1.01% | −3.50% | 0.013 | 0.911 |
| Negative groups | 12 | 28 | 30.00% | ||||||
|
| |||||||||
| PT(a) (%) | Positive groups | 17 | 52 | 28.81% | 0.77 | −8.69% | −30.15% | 2.020 | 0.155 |
| Negative groups | 15 | 25 | 37.50% | ||||||
|
| |||||||||
| AFP (ng/mL) | Positive groups | 24 | 25 | 48.98% | 2.99 | 32.59% | 66.53% | 13.511 | 0.000 |
| Negative groups | 10 | 51 | 16.39% | ||||||
|
| |||||||||
| GP73 (ng/mL) | Positive groups | 27 | 64 | 29.67% | 0.89 | −3.66% | −12.35% | 0.096 | 0.757 |
| Negative groups | 6 | 12 | 33.33% | ||||||
|
| |||||||||
| AFP-L3 (ng/mL) | Positive groups | 22 | 20 | 52.38% | 2.92 | 34.47% | 65.81% | 14.292 | 0.000 |
| Negative groups | 12 | 55 | 17.91% | ||||||
|
| |||||||||
| L3/AFP ratio | Positive groups | 18 | 19 | 48.65% | 2.34 | 27.82% | 57.18% | 8.958 | 0.003 |
| Negative groups | 15 | 57 | 20.83% | ||||||
HCC: patients who had developed HCC during the study period; non-HCC: patients who had not developed HCC during the study period; n: number of patients.